A new peer-reviewed study published in Kidney Blood Press Res highlights how multiple drug classes — including SGLT2 inhibitors, non-steroidal mineralocorticoid receptor antagonists (MRAs), and GLP-1 receptor agonists like Ozempic and Wegovy — are now being recommended for chronic kidney disease, even in patients who don't have diabetes. The findings matter because kidney disease affects millions and treatment options are rapidly expanding.
What the Research Looked At
Non-diabetic kidney disease (NDKD) is described in the study as a major contributor to chronic kidney disease (CKD) worldwide. For decades, the standard treatment has been renin-angiotensin system inhibitors (RASi) — a class of blood pressure drugs. But according to the new publication, three additional drug classes are now clinically recommended alongside them:
- SGLT2 inhibitors (SGLT2i) — originally developed as diabetes medications, these drugs reduce glucose reabsorption in the kidneys
- Non-steroidal mineralocorticoid receptor antagonists (non-steroidal MRAs) — a newer class that targets hormonal pathways involved in kidney scarring and inflammation
- GLP-1 receptor agonists (GLP-1 RA) — the class that includes semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound)
The study's title specifically notes "divergent" renal benefits between SGLT2 inhibitors and MRAs, suggesting these drug classes protect the kidneys through meaningfully different biological mechanisms.
Why This Matters If You're on a GLP-1 Medication
GLP-1 medications are best known for managing blood sugar and supporting weight loss, but growing research suggests they also offer organ-protective benefits — including for the kidneys and heart. This study's inclusion of GLP-1 receptor agonists alongside SGLT2 inhibitors and MRAs in the context of kidney disease signals that doctors are increasingly viewing these drugs as part of a broader toolkit for kidney protection, not just metabolic conditions.
Importantly, this research focuses on non-diabetic kidney disease, meaning the potential kidney benefits being studied apply to a wider patient population than previously recognized.
Key takeaway: GLP-1 medications like Ozempic and Wegovy are now being studied and recommended alongside other kidney-protective drugs for chronic kidney disease — even in patients without diabetes — suggesting their benefits may extend well beyond blood sugar and weight management.
What's Still Unknown
The abstract notes that these drug classes are now "recommended in clinical" settings, but the full published study would be needed to evaluate specific trial data, dosage findings, or head-to-head comparisons between the drug classes. The word "divergent" in the title suggests SGLT2 inhibitors and MRAs don't protect kidneys in the same way, but the precise mechanisms and patient populations that benefit most require a full review of the paper's findings.
What to Watch Next
Kidney disease treatment guidelines are evolving quickly. Researchers and clinicians are working to understand which patients benefit most from which combination of these newer drug classes. If you have chronic kidney disease — with or without diabetes — this is an active and fast-moving area of medicine worth discussing with your care team. Future studies are likely to clarify how GLP-1 medications fit alongside SGLT2 inhibitors and MRAs in personalized kidney treatment plans.
Frequently Asked Questions
This research reflects a rapidly changing landscape in kidney disease treatment. If you are taking a GLP-1 medication and have concerns about your kidney health, speak with your prescriber or a nephrologist to understand what the latest evidence means for your individual care plan.
- Peer-reviewed journal article, 'Divergent renal benefits of SGLT2 inhibitors and mineralocorticoid receptor antagonists in non-diabetic kidney disease,' Kidney Blood Press Res, date not specified.